Pressmeddelande -
Scandinavian Biopharma welcomes Sara Grahm to the position as Director of Manufacturing
Scandinavian Biopharma continues to strengthen its organization in manufacturing and is pleased to welcome Sara Grahm as our new Director of Manufacturing.
Sara, who has a master’s degree in chemistry, has a long and broad experience in the pharmaceutical industry. She most recently came from Sobi (Swedish Orphan Biovitrum) where she led strategic projects, was responsible for PMO (project management office) and Operational Excellence within the manufacturing organization. Prior to that, she was Head of Production at Recipharm and before that at AstraZeneca in roles in production, supply chain, quality and facility management.
- It will be great to take over the overall manufacturing responsibility for the ETEC vaccine candidate ETVAX®. The feeling and the opportunity to personally be able to influence to such a large extent is very stimulating in a company like Scandinavian Biopharma. In this position, I also benefit greatly from all my previous work experiences and can connect all the parts, says Sara Grahm.
- With her broad experience, combined with previous senior management positions in pharmaceutical manufacturing, Sara is just the right person to lead our manufacturing team. We are very happy to have Sara on board, says Björn Sjöstrand, CEO of Scandinavian Biopharma.
Ämnen
Kategorier
About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease. ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e. impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.
ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.
About ETVAX®
To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.
